Clinical trial NCT04225806: Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System - INFINITE-US
Official title: Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System (INFINITE-US)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Chronic Venous Insufficiency (CVI)
Deep Vein Reflux
Lead sponsor: Intervene, Inc.
Sponsor class: INDUSTRY
First posted: 2020-01-13
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: Prospective, non-randomized, multicenter pre-market early feasibility study (EFS) to evaluate subjects treated with the BlueLeaf System for the treatment of symptomatic CVI of the lower extremity

Detailed description: The purpose of this early feasibility study is to provide information on the BlueLeaf System for the formation of one or more autogenous vein valves constructed from the vein wall of the femoral and/or popliteal vein, in subjects with CVI and who meet the specified eligibility criteria. In particular, the safety and technical feasibility of the procedure will be validated in patients in the United States, including the procedural steps, operator technique, and subject characteristics. The study will assess the safety and effectiveness of the study device acutely and through 5 years.

Eligibility criteria: Key Inclusion Criteria

* Failed at least 6 months of conservative therapy at some point during the course of their CVI management (symptoms not adequately resolved or patient non-compliant/unable to tolerate)
* Deep system venous reflux characterized by \>1 second reflux time in two vein segments (vein segments defined as: proximal femoral, distal femoral, and popliteal), as assessed by duplex ultrasound (DUS) with patient in the standing position
* Presence of at least two potential target sites within a target vessel as assessed preliminarily by DUS, with a target site being defined as a segment within the femoral or popliteal vein that is:

  7mm to 11mm in luminal diameter and at least 3cm long and absent features that, in the Investigator's opinion, would preclude formation of a monocuspid valve (at any orientation).
* In the Investigator's opinion, the subject is a good candidate for treatment with the BlueLeaf System based on their symptoms, quality of life, anatomy, and the likelihood of benefit from continued conservative therapy

Key Exclusion Criteria:

* Untreated significant superficial venous incompetence which, in the opinion of the Investigator, may be the primary source of existing symptoms
* Acute deep venous thrombosis (DVT) within 1 year of consent
* Deep venous intervention (includes stenting) in the target limb or outflow vessels within 3 months of consent
* Flow-limiting venous outflow obstruction central to the intended target sites, defined by a common femoral vein duplex exam found to have a continuous waveform without respiratory variation
* Contraindications to all protocol specified anticoagulation options
* Known and uncontrolled hypercoagulopathy (i.e. hypercoagulopathy that cannot be adequately managed/controlled with medication)
* Women on long-term oral contraceptives
* Non-ambulatory patients
* Significant peripheral arterial disease with an ankle-brachial index of \< 0.70 or with incompressible vessels
* New York Heart Association Class III or IV heart failure
* Patients with a history of right heart failure occurring as a consequence of, for example, biventricular failure, intrinsic pulmonary disease, chronic thromboembolic pulmonary hypertension, and other etiologies that result in elevated right-sided pressures.
* Active systemic infection
* Invasive surgical procedure within the last 3 months that in the Investigator's opinion would interfere with the study procedure or results
* Chronic renal insufficiency with creatinine level of ≥ 2mg/dL
* Hemoglobin level \< 9.0 mg/dL
* Platelet count \< 50,000 or \> 1,000,000/mm3
* Total white blood cell count \< 3,000/mm3
* Subject is enrolled in another clinical study that, in the opinion of the Investigator, may c
* Comorbidity risks or other concerns which, in the opinion of the Investigator, either limits longevity or likelihood of complying with the protocol and its prescribed follow up (e.g. recent cancer or stroke); or precludes patient from being transitioned to open surgery if complication requiring surgical intervention occurs during the procedure (such as severe vein laceration).

Primary outcomes:
measure: Primary Safety Endpoint: The number of subjects experiencing a major adverse event (MAE), composed of the following
timeFrame: 30 day follow up
measure: Change in revised Venous Clinical Severity Score (rVCSS) from baseline
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Darien
country: United States
facility: The Vascular Experts
state: Connecticut
city: New York
country: United States
facility: NYU Langone Medical Center
state: New York
city: Chapel Hill
country: United States
facility: University of North Carolina at Chapel Hill
state: North Carolina
city: Pittsburgh
country: United States
facility: Allegheny General Hospital
state: Pennsylvania
city: Norfolk
country: United States
facility: Sentara Vascular Specialists
state: Virginia
Study officials:
References: